IGM BIOSCIENCES INC (IGMS) Stock Price, Quote, News and Overview
NASDAQ:IGMS - Nasdaq - US4495851085 - Common Stock - Currency: USD
IGMS Quote, Performance and Key Statistics
IGM BIOSCIENCES INC
NASDAQ:IGMS (2/5/2025, 2:47:10 PM)
1.625
+0.05 (+3.5%)
The current stock price of IGMS is 1.625 USD. In the past month the price decreased by -76.07%. In the past year, price decreased by -89.17%.
IGMS Latest News, Press Releases and Analysis
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ: IGMS). Such investors...
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and...
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
IGMS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.97 | 339.27B | ||
| AMGN | AMGEN INC | 15.5 | 165.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 962.15 | 126.37B | ||
| GILD | GILEAD SCIENCES INC | 22.61 | 124.85B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.72 | 78.84B | ||
| ARGX | ARGENX SE - ADR | N/A | 40.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.63B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.35B | ||
| NTRA | NATERA INC | N/A | 23.28B | ||
| BIIB | BIOGEN INC | 8.94 | 21.26B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.68 | 15.93B |
Related stock screener links
About IGMS
Company Profile
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 198 full-time employees. The company went IPO on 2019-09-18. The firm is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. The company is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
Company Info
IGM BIOSCIENCES INC
325 E Middlefield Rd
Mountain View CALIFORNIA 94043 US
CEO: Fred Schwarzer
Employees: 198
Company Website: https://igmbio.com/
Investor Relations: https://investor.igmbio.com/
Phone: 16509657873
IGMS FAQ
What is the stock price of IGMS?
The current stock price of IGMS is 1.625 USD.
What is the symbol for IGM BIOSCIENCES INC stock?
The exchange symbol of IGM BIOSCIENCES INC is IGMS and it is listed on the Nasdaq exchange.
On which exchange is IGMS stock listed?
IGMS stock is listed on the Nasdaq exchange.
Is IGMS a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for IGMS, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of IGMS.
Does IGMS stock pay dividends?
IGMS does not pay a dividend.
What is the Price/Earnings (PE) ratio of IGMS?
IGMS does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.64).
What is the Short Interest ratio of IGMS stock?
The outstanding short interest for IGMS is 9.01% of its float.
IGMS Technical Analysis
IGMS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IGMS. IGMS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
IGMS Financial Highlights
Over the last trailing twelve months IGMS reported a non-GAAP Earnings per Share(EPS) of -3.64. The EPS decreased by 27.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -72.2% | ||
| ROE | -278.47% | ||
| Debt/Equity | 0 |
IGMS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 79% to IGMS. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of 27.97% and a revenue growth 13.48% for IGMS